FRLN — Freeline Therapeutics Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $28.24m
- -$1.21m
- 22
- 17
- 67
- 27
Annual cashflow statement for Freeline Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -33.3 | -53.9 | -96.3 | -140 | -89 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.114 | 1.46 | 6.28 | 10.9 | 0.096 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.43 | -1.41 | -6.68 | 19.7 | 8.77 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -25.8 | -52.3 | -95 | -108 | -78.5 |
| Capital Expenditures | -3.75 | -3.02 | -2.51 | -4.27 | -7.01 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | 0.126 | 0 | 0 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -3.75 | -3.02 | -2.39 | -4.27 | -7.01 |
| Financing Cash Flow Items | — | — | — | -1.16 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 38.1 | 115 | 243 | -0.984 | 27.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.8 | 58.2 | 157 | -113 | -70.5 |